(USD) | Dec 2023 | Q/Q |
---|---|---|
Revenue | 8.2B | +19% |
Gross Profit | 5.1B | - |
Cost Of Revenue | 3.1B | +72% |
Operating Income | 1.3B | -37% |
Operating Expenses | 3.8B | - |
Net Income | 767MM | -56% |
R&D | 1.5B | +42% |
G&A | 2.3B | +68% |
Amortization | 1.1B | +62% |
Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
Amgen stock neared its record high Friday after the company said it's "very encouraged" with midstage test results for its obesity treatment.
Apple reports better-than-estimated earnings and expands its buyback program by $110 billion, Amgen ‘very encouraged’ by preliminary data from a trial of a weight-loss drug, and Expedia reduces its sales outlook for the year.
Here's what could happen next to Amgen shares.
Traders have pulled forward their expectations for the first interest rate cuts in the US as the economy added fewer jobs than expected.
**Apple (AAPL)**: The iPhone maker authorized $110 billion in stock buybacks and forecast a return to revenue growth in the current quarter. Apple shares climbed more than 6%. **Amgen (AMGN)**: The drug manufacturer's chief executive said he was “very encouraged” by early data for its experimental obesity treatment.
A weak April jobs report fueled a wave of buying in the stock market today. Apple and Amgen were strong gainers in the Dow Jones.
Top Midday Stories: Apple's Dividend, Buybacks Announcements; Amgen Obesity Drug Trial Results; Exxon Completes Pioneer Acquisition
Wall Street's main indexes advanced on Friday after a softer-than-expected jobs report revived hopes of the Federal Reserve cutting interest rates this year, while gains in Apple and Amgen also helped. U.S. job growth slowed more than expected in April and the increase in annual wages fell below 4% for the first time in nearly three years.
Amgen (AMGN) beats first-quarter 2024 estimates for earnings and sales. Amgen is "very encouraged" by interim data from the phase II study on obesity candidate MariTide.
The competition among weight-loss drugs is heating up as Amgen (AMGN) reports positive early results from the development of its GLP-1 weight-loss drug, MariTide. The pharmaceutical company also topped first-quarter revenue estimates despite reporting a loss of $113 million. Yahoo Finance Senior Health Reporter Anjalee Khemlani breaks down how competition in the obesity drug market is ramping up as drug manufacturers find new medical use cases for this class of drugs. She refers back to comments...